{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:40:30Z","timestamp":1772217630474,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Renal Care"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Various populations are affected by chronic kidney disease (CKD), and a low dose appetite stimulant megestrol acetate (MA) is sometimes recommended in patients with CKD to ameliorate protein\u2010energy wasting (PEW). Patients with CKD are at greater risk of developing PEW since the progression of their disease can cause decreased nutrient intake, catabolic effects, systemic inflammation and metabolic changes. Providers can detect PEW in CKD by identifying low serum levels \u22643.8\u2009g\/dl of albumin, &lt;30\u2009mg\/dl of transthyretin, or &lt;100\u2009mg\/dl of cholesterol. Other characteristics include BMI &lt;22\u2009kg\/m<jats:sup>2<\/jats:sup> (for \u226465 years), unintentional weight loss of \u22655% in three months or \u226510% in six months, body fat percentage &lt;10%, with muscle wasting of a reduction of \u22655% in three months or \u226510% in six months of muscle mass.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A review of research was completed and data collected from small population\u2010based retrospective studies to determine the effect of MA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Clinical trials demonstrated the effectiveness of MA by showing increases in BMI up to 9%, albumin levels up to 1.1\u2009g\/dl, with reported protein and energy intake increases from 27% to 42%. There are potential adverse effects of using MA in CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After reviewing the available literature, the benefits of using MA should be evaluated against the potential side effects. For further examination of MA's potential benefits, long\u2010term, prospective, large clinical trials should be carried out.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jorc.12138","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T06:19:20Z","timestamp":1446704360000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Using megestrol acetate to ameliorate protein\u2010energy wasting in chronic kidney disease"],"prefix":"10.1111","volume":"42","author":[{"given":"Christine Skouberdis","family":"Smith","sequence":"first","affiliation":[{"name":"Division of Nephrology Levine Children's Hospital\u2010Carolinas Healthcare System Charlotte North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John V.","family":"Logomarsino","sequence":"additional","affiliation":[{"name":"Department of Human Environmental Studies Central Michigan University Mount Pleasant Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1529-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2605.2001.00291.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/089686089501500307","article-title":"Growth hormone and malnutrition in dialysis patients","volume":"15","author":"Blake P.G.","year":"1995","journal-title":"Peritoneal Dialysis International"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-2276(00)90021-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.12.025"},{"key":"e_1_2_9_7_1","first-page":"CD008190","article-title":"Appetite stimulants for people with cystic fibrosis","volume":"27","author":"Chinuck R.","year":"2014","journal-title":"Cochrane Database Systematic Reviews"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2008.10.006"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200519030-00004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-011-0025-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2010.01.010"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.147"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.93743"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006010034"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199801010-00007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012010047"},{"key":"e_1_2_9_17_1","first-page":"1","article-title":"Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers","volume":"1","author":"Kim Y.H.","year":"2014","journal-title":"Clinical Therapies"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2612-7"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2008.11.003"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/381977"},{"key":"e_1_2_9_21_1","first-page":"473","article-title":"Urinary excretion of different corticosteroid\u2010metabolites in oral contraception and pregnancy","volume":"60","author":"Nielsen M.D.","year":"1969","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2006.1863"},{"key":"e_1_2_9_23_1","first-page":"205","volume-title":"Food\u2010Medication Interactions","author":"Pronsky Z.M.","year":"2012"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrn.2004.10.006"},{"key":"e_1_2_9_25_1","first-page":"CD004310","article-title":"Megestrol acetate for treatment of anorexia\u2010cachexia syndrome","volume":"28","author":"Ruiz Garcia V.","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Journal of Renal Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjorc.12138","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjorc.12138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jorc.12138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:58:05Z","timestamp":1695729485000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jorc.12138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/jorc.12138"],"URL":"https:\/\/doi.org\/10.1111\/jorc.12138","archive":["Portico"],"relation":{},"ISSN":["1755-6678","1755-6686"],"issn-type":[{"value":"1755-6678","type":"print"},{"value":"1755-6686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]},"assertion":[{"value":"2015-11-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}